FATE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.15 USD | +1.72% |
|
-1.66% | +10.96% |
| May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
| May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 5.85M | Sales 2025 * | 5.24M | Capitalization | 472M |
|---|---|---|---|---|---|
| Net income 2024 * | -201M | Net income 2025 * | -221M | EV / Sales 2024 * | 51.6 x |
| Net cash position 2024 * | 170M | Net cash position 2025 * | 126M | EV / Sales 2025 * | 66.1 x |
| P/E ratio 2024 * |
-2.33
x | P/E ratio 2025 * |
-2.38
x | Employees | 181 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fate Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +1.72% | ||
| 1 week | -1.66% | ||
| Current month | +5.06% | ||
| 1 month | -28.08% | ||
| 3 months | -35.05% | ||
| 6 months | +108.54% | ||
| Current year | +10.96% |
1 week
3.58
4.54
1 month
3.585.96
Current year
3.468.83
1 year
1.638.83
3 years
1.6397.43
5 years
1.63121.16
10 years
1.46121.16
| Managers | Title | Age | Since |
|---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
| Chairman | 76 | 11-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.95% | 0 M€ | 0.00% | - | |
| 2.10% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 4.15 | +1.72% | 2,817,543 |
| 24-05-10 | 4.08 | +4.62% | 6,458,162 |
| 24-05-09 | 3.9 | +5.41% | 3,902,975 |
| 24-05-08 | 3.7 | -4.64% | 2,918,187 |
| 24-05-07 | 3.88 | -8.06% | 1,983,083 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
4.15
USD
Average target price
6.933
USD
Spread / Average Target
+67.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.96% | 472M | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -2.27% | 21.93B | |
| -12.15% | 22.34B | |
| -5.57% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
- Stock Market
- Equities
- FATE Stock
